https://www.selleckchem.com/pr....oducts/fasoracetam-n
5% at one month, 9.5% at threemonths, and 20% at six months. This risk leveled off near 12 to 18months. While the cumulative risk of intracranial hypertension recurrence increases most dramatically within the first sixmonths after medication wean, it does not appear to taper until 12 to 18months. Given the possibility of delayed or asymptomatic recurrences, long-term follow-up is ideal, although patients can likely be seen less frequently after the first 12 to 18months after medication wean. While the cumulative risk of intra
Like
Comment
Share
